Cipla Q4FY26 Results: Profit drops 54.6% to Rs 554.6 crore; board recommends Rs 13 final dividend

Cipla Q4 Results: Pharma major Cipla Limited reported a sharp decline in earnings for the fourth quarter of FY26, with consolidated net profit falling 54.6 per cent year-on-year to Rs 554.6 crore.

The company had posted a net profit of Rs 1,221.8 crore in the corresponding quarter last year.

Post earnings announcement, Cipla shares were trading at Rs 1322.50, up 2.34 per cent or 30.20 points as of 12:55 pm.

Revenue declines 3 per cent

Revenue from operations for the quarter stood at Rs 6,451.2 crore, down 3 per cent from Rs 6,730 crore reported in the year-ago period.

The weaker topline performance was accompanied by pressure on operating profitability during the quarter.

EBITDA and margins under pressure

EBITDA for the quarter came in at Rs 955 crore, registering a decline of 38 per cent compared with Rs 1,537.6 crore in the same quarter last year.

Operating margin contracted sharply to 14.6 per cent from 22.8 per cent in the year-ago period, reflecting weaker operating leverage and profitability pressure.

Board recommends Rs 13 final dividend

Despite the weaker quarterly performance, the board of Cipla Limited has recommended a final dividend of Rs 13 per equity share of face value Rs 2 each for the financial year ended March 31, 2026.

The dividend recommendation, announced as part of the company’s May 13, 2026 earnings release, remains subject to shareholder approval.

Investors watch for recovery signals

Market participants are expected to closely monitor management commentary around margin recovery, domestic formulations growth and international business performance following the sharp drop in quarterly profitability.

The pharmaceutical sector continues to face pricing pressure, regulatory costs and demand fluctuations across key export markets, factors that remain important for earnings visibility going forward.